Hikma Pharmaceuticals (HIK) has parted ways with its chief executive Riad Mishlawi two years after he assumed the helm at the generic injectables business. The company said the change had been by mutual agreement. The shares were marginally down in morning trading, but the 23 per cent decline in Hikma’s share price over the past 12 months reflects a difficult generics market.
Said Darwazah, Hikma’s executive chair and former CEO, will assume all operational responsibilities with immediate effect. The company emphasised that none of its guidance had changed since a trading update in November; this means that group revenue is still expected to grow in the range of 4-6 per cent, with a slightly narrower core operating profit coming in between $730mn (£557mn) to $750mn.
Senior management changes have happened quickly at the company. In November, the head of Hikma’s injectables division, Dr Bill Larkins, announced that he was leaving at the end of the year.




